ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
December 20 2023 - 9:04AM
Business Wire
Tru Niagen is now available to US troops
through an exclusive Military program
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) and healthy aging
research, is proud to announce its inaugural initiative to support
the US Military.
As the most efficient, studied, and high-quality NAD+ boosting
supplement on the market, ChromaDex’s patented nicotinamide
riboside (NR) supplement, Tru Niagen®, is now being utilized by US
Military Special Operations Forces, marking a significant milestone
in the product's journey toward promoting cellular health and
resilience. In a gesture of gratitude and further support US
troops, ChromaDex has launched an exclusive program that offers Tru
Niagen products to active and veteran Military Service Members.
This initiative reflects ChromaDex’s commitment to the health and
well-being of those who serve the Nation.
NAD+ is an essential coenzyme vital for cellular health and NR
is the most efficient way to elevate NAD+ levels due to its ability
to cross directly through the cell membrane. Clinically proven to
safely and effectively increase NAD+, Tru Niagen supports cellular
energy, combats physiological stress, and aids in cellular repair
and recovery – all of which are vital for the physically demanding
environments encountered in military operations.
"We are honored that Tru Niagen will play a role in the health
and wellness of our troops,” said Rob Fried, CEO of ChromaDex.
“This further underscores the significance of NAD+ in physically
demanding professions."
As the gold standard NAD+ boosting supplement, Tru Niagen
embodies the highest scientific rigor and quality standards and is
backed by two Nobel Prize winners, 30+ human clinical studies, 300
published scientific studies, and accepted by the world’s most
rigorous regulatory bodies. Tru Niagen products are certified by
NSF for Sport, Alkemist Labs, Star-K (Kosher), and IFANCA (Halal)
and every lot of Tru Niagen is tested for potency, safety, and
purity. Certificates of analysis are readily available so each
bottle can be traced directly to ChromaDex’s ISO/IEC 17025:2017
accredited laboratory.
"As a clinician focused on the nexus of health and performance,
I recognize the paramount importance of cellular health and
mitochondrial optimization. This is particularly true in
high-stress, physically demanding environments like those faced by
military personnel. Tru Niagen stands out as the leading,
gold-standard NAD+ supplement in this regard. Its ability to
effectively boost NAD+ levels and support mitochondrial function is
crucial for maintaining cellular resilience, energy metabolism, and
overall cellular repair. Further, it features patented nicotinamide
riboside (NR), which is the most efficient NAD+ precursor
available. These benefits are essential for military members who
regularly encounter extreme physical and psychological stress.
Incorporating Tru Niagen into their regimen can be a game-changer
in optimizing their performance and recovery, ensuring they are
always mission-ready," remarked Dr. Jim Lavalle, Clinical
Pharmacist, CEO of Metabolic Code Enterprises, and ChromaDex
Consultant.
This initiative highlights ChromaDex's dedication to continuing
to pioneer NAD+ research and its commitment to providing
high-quality, science-backed products. As the leading NAD+ boosting
supplement available, Tru Niagen has already made a significant
impact on the health and wellness industry, and its adoption by the
US Military is a testament to its effectiveness, quality, and
reliability.
For more information about Tru Niagen’s military discount
program, please visit https://discover.truniagen.com/military/. If
you are an active or veteran US Military Service Member interested
in purchasing Tru Niagen, please email military@chromadex.com for
more details.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to incorporating Tru Niagen
into the regimen of the military personnel can be a game-changer in
optimizing their performance and recovery. Statements that are not
a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. Risks that contribute to the uncertain
nature of these forward-looking statements include the impact of
the COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2022, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231220875928/en/
ChromaDex Media Contact: Kendall Knysch, Head of Media
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024